Neuronetics Holds Annual Meeting, Elects Directors

Neuronetics ( (STIM) ) has provided an announcement.

On May 22, 2025, Neuronetics, Inc. held its Annual Meeting of Stockholders, where 81.38% of eligible shares were represented. During the meeting, all director nominees were elected for a one-year term, KPMG LLP’s appointment as the independent auditor for 2025 was ratified, and executive compensation for 2024 was approved. However, a proposal to eliminate supermajority voting requirements in the company’s governance documents was not approved.

The most recent analyst rating on (STIM) stock is a Buy with a $5.50 price target. To see the full list of analyst forecasts on Neuronetics stock, see the STIM Stock Forecast page.

Spark’s Take on STIM Stock

According to Spark, TipRanks’ AI Analyst, STIM is a Neutral.

The most significant factor is the ongoing financial challenges, including consistent losses and cash flow issues, which weigh heavily on the score. While the earnings call provided some positive long-term guidance, short-term financial health remains a concern. Technical indicators suggest neutral sentiment, and valuation metrics highlight profitability challenges.

To see Spark’s full report on STIM stock, click here.

More about Neuronetics

Neuronetics, Inc. operates in the medical device industry, focusing on developing non-invasive therapies for psychiatric disorders. The company is known for its NeuroStar Advanced Therapy system, which is used for the treatment of major depressive disorder.

Average Trading Volume: 1,118,789

Technical Sentiment Signal: Buy

Current Market Cap: $261.3M

See more data about STIM stock on TipRanks’ Stock Analysis page.